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Abstract

BACKGROUND: Ongoing research seeks to identify bloodbased biomarkers able to predict onset and progression of
Alzheimer’s disease (AD).
OBJECTIVE: The unfolded conformational variant of
p53 (U-p53 AZ), previously observed in AD individuals, was
evaluated in plasma samples from individuals participating
in the Australian Imaging, Biomarkers and Lifestyle (AIBL)
cohort for diagnostic and prognostic assessment, validated on
a neuropsychological-based diagnosis, over the course of six
years.
DESIGN: Retrospective Longitudinal Prognostic biomarker
study.
SETTING: Single-center study based on the AIBL cohort.
PARTICIPANTS: 482 participants of the AIBL cohort, aged
60-85 years, without uncontrolled diabetes, vascular disease,
severe depression or psychiatric illnesses.
MEASUREMENTS: The AlzoSure® Predict test, consisting of
immunoprecipitation (IP) followed by liquid chromatography
(LC) tandem mass spectrometry (MS/MS), was performed
to quantify the AZ 284® peptide as readout of U-p53AZ and
compared with an independent neuropsychological diagnosis.
The amyloid load via amyloid β-positron emission tomography
(Aβ-PET) and supporting clinical information were included
where possible.
RESULTS: U-p53 AZ diagnostic and prognostic performance
was assessed in both time-independent and time-dependent
(36, 72 and 90 months following initial sampling) analyses.
Prognostic performance of Aβ-PET and survival analyses
with different risk factors (gender, Aβ-PET and APOE ε4
allele status) were also performed. U-p53 AZ differentiated
neuropsychologically graded AD from non-AD samples, and
its detection at intermediate/high levels precisely identified
present and future symptomatic AD. In both time-independent
and time-dependent prognostic analyses U-p53AZ achieved area
under the curve (AUC) >98%, significantly higher than Aβ-PET
AUCs (between 84% and 93%, P respectively <0.0001 and
<0.001). As single factor, U-p53AZ could clearly determine the
risk of AD neuropsychological diagnosis over time (low versus
intermediate/high U-p53AZ hazard ratio=2.99). Proportional
hazards regression analysis identified U-p53AZ levels as a major
independent predictor of AD onset.
CONCLUSIONS: These findings support use of U-p53 AZ as
blood-based biomarker predicting whether individuals would
reach neuropsychologically-defined AD within six years
prior to AD diagnosis. Integration of U-p53 AZ in screening
processes could support refined participant stratification for
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interventional studies.
Key words: Alzheimer’s disease, blood-based biomarker, AD, p53,
prognosis, U-p53.
Abbreviations: Aβ: Amyloid beta; AIBL: Australian Imaging,
Biomarkers and Lifestyle; AUC: Area under the receiver operating
characteristic curve; AD: Alzheimer ’s disease; APOE ε4:
Apolipoprotein E ε4 allele; BACE1: β-site amyloid precursor proteincleaving enzyme 1; CI: Confidence interval; CN: Cognitively normal;
CSF: Cerebrospinal fluid; ELISA: Enzyme linked immunosorbent
assay; ESI: Electrospray ionization; HCD: Higher energy
collision-induced dissociation; HPLC: High performance liquid
chromatography; IP: Immunoprecipitation; MCI: Mild cognitive
impairment; MRI: Magnetic resonance imaging; MS/MS: Tandem
mass spectrometry; OD: Other types of dementias; PiB-PET:
Positron emission tomography utilizing Pittsburgh compound B;
ROC: Receiver operating characteristic; PTMs: Post-translational
modifications; ROS/RNS: Reactive oxygen/reactive nitrogen species;
U-p53: Unfolded p53.

Introduction

A

lzheimer's disease (AD) is a progressive
neurodegenerative disorder, starting with
an asymptomatic phase of normal cognition
lasting approximately two decades. While some
individuals experience subjective memory complaints
(SMC), all eventually progress to mild cognitive
impairment (MCI) before finally reaching the AD stage
(1, 2). To date, the formal diagnosis of AD dementia, as
stated by the National Institute on Aging and Alzheimer’s
Association (NIA-AA), relies on neuropsychological tests
further confirmed by brain imaging and cerebrospinal
fluid (CSF) sampling (3).
For more than 15 years, different disease-modifying
treatments (DMTs) have been investigated, yet none of
them were found to be clinically effective, (4-6) except
for aducanumab, which was recently approved by the
Food and Drug Administration (FDA) for treatment of
AD dementia at the MCI stage (7, 8). However, earlier
interventions remain unavailable, increasing the need
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for cost-effective screening biomarkers for early stage
prevention clinical trials. The search for effective DMTs
would largely benefit from stratification of high-risk
participants in clinical trials by the implementation of
minimally-invasive blood-based biomarkers that can
reliably predict AD in cognitively normal (CN)
individuals (9, 10). The pathogenic features of AD that
have an onset in the asymptomatic phase may allow
identification of early blood-based biomarkers (11,
12). By eliciting compensatory responses, these early
pathogenic changes were found to initially prevent the
increase in reactive oxygen and nitrogen species (ROS/
RNS) through activation of antioxidant mechanisms.
However, these compensatory antioxidant responses
become inefficient throughout the AD continuum,
resulting in progressive oxidative stress exacerbation (1316). This increase in oxidative stress has been described
to induce redox post-translational modifications (PTMs)
of the p53 protein, altering its native structure and
disrupting its physiological functions (17). Besides redox
PTMs, in vitro experiments have shown that nanomolar
concentrations of Aβ 1-40 and Aβ 1-42 can induce similar
alterations in the tertiary structure of p53, previously
described as the unfolded p53 conformational variant
(U-p53) (18-20). Accordingly, higher levels of U-p53
have been consistently detected in peripheral cells
derived from patients with AD as compared with
controls (21-23). Recently, a novel antibody (2D3A8)
was developed to detect this AD-specific U-p53 variant
(herein described as “U-p53AZ”) (24), demonstrating its
promising performance in predicting the AD risk at the
asymptomatic and symptomatic stages (24, 25).
In the present study, we 1) investigated U-p53 AZ
abundance across neuropsychologically defined
diagnostic groups (no memory complaints [NMC], SMC,
MCI and AD), 2) tested the diagnostic performance of
both U-p53 AZ and the amyloid burden (Aβ) to detect
AD neuropsychological status, and 3) assessed the
prognostic performance of U-p53 AZ in differentiating
individuals at risk of developing AD from individuals
with stable diagnoses. With these analyses we thus
further confirm the potential of U-p53AAZ as a reliable
and minimally-invasive blood-based biomarker to
predict the neuropsychological onset of AD in cognitively
normal (CN, asymptomatic) or MCI (early symptomatic)
individuals.

Materials and methods
Subjects
The plasma samples and supporting clinical
information were provided by the Australian Imaging,
Biomarkers and Lifestyle (AIBL) longitudinal cohort
study, active since 2006 (26, 27). In total, 482 subjects
aged between 60 and 85 years who did not present
specific comorbidities (uncontrolled diabetes, vascular

disease, severe depression, or psychiatric illnesses) were
included in this retrospective study, collecting a blood
sample for each included subject from the AIBL study
by applying a consecutive sampling approach. Subjects
were followed-up every 18 months. At each visit, the
neuropsychological status and medical history were
reviewed by a neuropsychologist and clinician. A clinical
review panel consisting of a geriatrician, a neurologist
and a neuropsychologist, blinded to amyloid β-positron
emission tomography (Aβ-PET) and biomarker status,
determined the diagnosis of CN, MCI and AD subjects.
Additionally, three subjects were defined to be affected by
other forms of dementia (OD), while some were classified
as OD by their last diagnosis. Data on the mini-mental
state examination (MMSE), clinical dementia rating Scale
(CDR) and amyloid brain burden (determined by PET
with the labelled Pittsburgh compound B [PiB-PET],
flutemetamol, florbetapir, or NAV4694) were collected.
Data on Aβ-amyloid burden was converted to the
100-points-based centiloid calibration scale (28) and
subjects were assigned to different amyloid categories
according to the following scoring in centiloid units
(CL): “Negative” <15 CL, “Uncertain” ≥15 CL and <25
CL, “Moderate” ≥25 CL and <50 CL, “High” ≥50 CL
and <100 CL, “Very high” ≥100 CL. Individuals with
missing imaging values were not included in some
analyses of this study. Based on the NINCDS-ADRDA
criteria, participants were classified as cognitive normal
(CN), MCI and symptomatic AD solely according to
their neuropsychological status and irrespective of
traditional markers as Aβ-PET status and tau. The CN
diagnostic group consisted of two subgroups: no memory
complaints (NMC) and subjective memory complaints
(SMC). The term “AD” herein used refers to AD as
defined on the neuropsychological status found in the
individuals and does not represent clinical AD based on
Aβ status. The appropriate institutional ethics committee
approved this study, which was carried out following
all relevant ethical regulations (Human Research Ethics
Committee, Research Governance Unit, St Vincent’s
Healthcare, Australia (no. 028/06)).

Blood processing and APOE alleles genotyping
A c c o rd i n g t o t h e A I B L s t a n d a rd o p e r a t i n g
procedures, blood samples were handled at room
temperature in EDTA collection tubes (S-Monovette®,
Sarstedt, Germany) preventively supplemented with
prostaglandin-E (final concentration: 33 ng/mL, Sapphire
Biosciences, Australia). Processing took place within three
hours from blood withdrawal, followed by aliquoted
sample storage in liquid nitrogen. Genotyping was
carried out as has been previously described (29).
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Immunoprecipitation (IP) and nanoflow
e l e c t ro s p r a y i o n i z a t i o n t a n d e m m a s s
spectrometry (ESI-MS/MS)
The 2D3A8 antibody selectively binds the AD-clinically
relevant U-p53 AZ (24, 30) and was here deployed to
identify peptides through protein sequencing via MS/
MS. Protein sequencing was performed at MyomicsDX
Inc. (MD, USA). IP took place on high abundance proteindepleted plasma samples with different antibodies. One
reaction was performed with 2D3A8 (10 μg/sample,
Diadem SpA, Italy), while the other was based on a
mixture of p53-specific antibodies at 10 μg/sample
(DO11:DO12:SAPU:KJC12, respective volume ratios
1:1:2:2 and final concentration of 1 μg/μl) (31, 32). Upon
enrichment, the peptides were eluted, fractionated
through an Agilent 1290 Infinity II liquid chromatography
(LC) system (Agilent, CA, USA) and analyzed in MS
by a Thermo Scientific™ Q Exactive Mass Spectrometer
(Thermo Fisher Scientific, MA, USA). Tandem mass
tag labelled peptides were analyzed by MS/MS in a
data-dependent approach on a Thermo Scientific™
EASY-nLC 1000™ HPLC system, coupled to a Thermo
Scientific EASYSpray™ source supported by an analytical
nanoflow column system (Thermo Fisher Scientific, MA,
USA). Acquisition of the survey full scan MS spectra (m/z
350−1800) was achieved with the Orbitrap with 35,000
resolution, following ion accumulation to a 3 × 106 target
value, selected on predictive automated gain control
based on the previous full scan. Sequential isolation of
the 10 most intense multiply charged ions (z ≥ 2) followed
and these were then fragmented in the Axial Higher
energy Collision-induced Dissociation (HCD) cell through
normalized HCD collision energy at 30% (automatic
gain control target: 1e5, maximal injection time: 400
ms, resolution: 35,000). The Proteome Discoverer 2.2
software (Thermo Fisher Scientific, MA, USA) processed
automatically the MS raw files, and Xtract was deployed
in addition to default spectrum selector node. The Mascot
search engine combined with Sequest HT (interfaced with
different processing nodes of Proteome Discoverer 2.2)
was used to address the searches. The final dataset was
reprocessed through the MyProt-QuantiR (MyOmicsDx
Inc., MD, USA) software package, allowing the
identification of the AZ 284® peptide sequence as the most
clinically relevant peptide in samples from individuals
affected by AD.

Sample preparation
Fractions of samples provided by the AIBL cohort (25
μL) underwent IP using the patented 2D3A8 monoclonal
antibody (30) (Diadem SpA, Italy) coupled to Protein L
magnetic beads (Thermo Fisher Scientific, MA, USA).
Upon protein enrichment, the samples were treated with
trypsin (3.5 hours at 37°C followed by 0.5 hours at 57°C).

AlzoSure® Predict test: measurement of U-p53AZ
in patient plasma samples
U-p53 AZ plasma levels were assessed through
quantization of the peptide AZ 284® by LC coupled to
electrospray ionization (ESI)-MS/MS at ISB srl (Italy).
A surveyor HPLC Thermofisher Quaternary Pump was
paired to a ThermoFisher mass spectrometer. For analyte
separation, a Phenomenex Kinetex PFP column (50x4.1
mm, 2.6 m, Phenomenex, CA, USA) was used and the
mobile phases were A (H 2O-0.2 % HCOOH, SigmaAldrich, MO, USA) and C (CH 3OH, Sigma-Aldrich,
MO, USA). LC was performed in a binary gradient at a
chromatographic flow of 0.2 mL/min: 2% of phase C was
maintained for 2 minutes and raised to 40% in 3 minutes
and maintained as such for 7 additional minutes. Phase C
was further raised to 70% 2 minutes later and kept at 70%
for 4 minutes before resetting to the starting conditions
for 5 minutes. A calibration curve was developed prior
to analysis of the clinical samples, spiking a negative
control of plasma with AZ 284® labelled peptide covering
the range between 0.02 fmol/10 μl and 4 fmol/10μl by
at least 4 different points. Peptide sequence was then
analyzed with a ThermoFisher Mass Spectrometer (TSQ
Vantage Thermo Fisher Scientific heated-ESI ion source,
MA, USA). The ion source parameters were: multiple
reaction monitoring scan; capillary temperature: 320°C;
collision energy: 5eV; sheath gas flow: 30 L/min; auxiliary
gas flow: 2 L/min; and sweep gas flow: 15 L/min. All
tests were performed while being blinded from the
clinical and cognitive data. In the present study, arbitrary
thresholds were temporarily defined to assign individuals
to pre-established categories, namely “low U-p53AZ” for
AZ 284® <0.76 fmol/10μl, “intermediate U-p53AZ” for 0.76
fmol/10μl ≤ AZ 284® <1.28 fmol/10μl and “high U-p53AZ”
for AZ 284® >1.28 fmol/10μl. The high level threshold
was set at the maximal Youden index that separates AD
from non-AD diagnoses at baseline, while the low level
threshold was determined similarly, but using the final
diagnosis instead.

Statistical analyses
The diagnostic and prognostic performance of U-p53AZ
to predict AD were assessed. The performance of amyloid
status (as measured by Aβ imaging, calibrated CL, or
inferred Aβ categories as reported above) was included
as reference at the diagnostic level and compared with
U-p53AZ at the prognostic level. Survival curves were
plotted on risk models based on U-p53AZ alone or a model
encompassing all the risk factors.
Diagnostic analyses were performed on the biomarker
data and neuropsychological assessments and the
analyses used measurements defined at the baseline
assessment (i.e., the sample corresponding to the visit
at which U-p53AZ was first measured). The diagnostic
performance was evaluated through two specific
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models based on the neuropsychological assessment:
1) comparing AD individuals with non-AD individuals
(including subjects in the study pooled from any other
diagnosis than AD) and 2) specifically comparing CN and
MCI subjects with AD subjects.
For prognostic evaluation, both time-independent
and time-dependent analyses were performed to verify
the potential of U-p53AZ in predicting the diagnosis of
AD. Time-independent analyses were structured using
the baseline measure of U-p53AZ and Aβ-PET to discern
AD-progressing individuals from stable non-AD subjects
based on their final neuropsychological diagnosis. Timedependent analyses of individuals regardless of the
neuropsychologically assigned status (AD versus nonAD) were included and compared when available with
information on amyloid status (considered positive for a
CL score ≥15). In a sub-cohort of samples with available
amyloid status data, the prognostic performance of
U-p53AZ was compared to the performance of the Aβ-PET
biomarker. In this comparison, non-AD individuals
for which their true disease status was unknown or
ambiguous due to lack of sufficient follow-up were rightcensored in these specific analyses.
A survival analysis with respect of AD-free survival
was performed excluding subjects with a baseline
neuropsychological AD diagnosis to assess the prognostic
value of U-p53 AZ from the baseline measurement. A
right-censored model was considered to be sufficiently
accurate and allowed the use of a semi-parametric Cox
proportional hazards model, based on 1) the considerably
larger median follow-up times for CN (67 months), MCI
(27 months) and OD (37 months) compared to the interval
period between patient visits (approximately 18 months)
during which AD onset could occur, and 2) the 20-month
median time to progression observed for those patients
whose neuropsychological status changed to AD. Cox
models were evaluated for 1) U-p53AZ alone (N=338),
or 2) along with other covariates (U-p53AZ, CL, baseline
age, gender and dichotomous APOE ε4 status; N=294).
Hazard ratios (HR) were then evaluated for all risk factors
in models adjusted or unadjusted to the factors and two
models (U-p53 AZ and a complete model including all
factors) were then plotted as Kaplan-Meier curves to
visualize the probability of AD onset according to the
risk strata. The analyses were obtained using survival,
survminer, and survcomp R packages. For direct HR
comparison, the continuous variables of the reference
model (U-p53AZ, Aβ-PET [CL] and age) were normalized
into standard scores by subtracting the mean from each
value and dividing by the standard deviation.
To evaluate diagnostic and prognostic performances,
receiver operating characteristic (ROC) curves were
generated and their corresponding area under the
curve (AUC) were calculated to determine the accuracy,
sensitivity, specificity, positive (PPV) and negative
predictive values (NPV), using the R-package bdpv.
Unless otherwise specified, cut-offs for sensitivity and

specificity were determined using the maximal Youden
J statistic, i.e. the sum of sensitivity and specificity.
Prognostic analyses were performed in R, using the pROC
and timeROC packages for time-independent and timedependent analyses respectively (33-35). ROC curve
analyses to determine the optimal cut-off were performed
using the cutpointr package (36).
Where applicable, numerical values were compared
using Student’s T test or ANOVA followed by Tukey’s
test for evaluation of pairwise differences. Differences in
follow-up time were evaluated using a non-parametric
Wilcoxon rank sum test with continuity correction.
Fisher’s exact test was used to evaluate categorical count
data. Comparison of ROC curves was performed through
the DeLong test, while NPV and PPV were defined at a
prevalence rate of AD of 30% at baseline and 45% at the
final diagnosis. All the mentioned analyses were carried
out in R.

Results
Demographics and characteristics of the study
cohort
In total, samples were included from 482 individuals
spanning the AD continuum. Three of these individuals
who were initially diagnosed with neuropsychological
AD, but afterwards with OD, were excluded from the
dataset due to lacking or persistently high amyloid
levels resulting in a non-congruent pathology. Out of the
479 included individuals, 422 (88%) and 472 (99%) had
available information on Aβ load (quantified by CL) and
APOE ε4 allele status (through genotyping), respectively.
The demographics and neuropsychological classification
at baseline, as well as the neuropsychological
classification at last follow-up, are shown in Table 1.
During the follow-up visits, a subset of participants
changed their neuropsychological classification towards
MCI, AD, or OD. Additional insight into the total number
of subjects changing neuropsychological classification
status can be found in Supplementary Material (Table
1). A flow of subjects across diagnostic and prognostic
analyses is also reported, in Supplementary Material
(Figure 1).

Levels of U-p53AZ in different diagnostic groups
The levels of U-p53 AZ were assessed by AZ 284 ®
quantization and visualized according to the baseline
neuropsychological classification, defined as NMC, SMC,
MCI and AD (Figure 1). Although U-p53AZ was similarly
distributed among individuals neuropsychologically
diagnosed as NMC and SMC, it was markedly increased
in individuals with MCI and AD. For statistical testing,
NMC and SMC were combined as a single group due
to the subjective nature of this grouping and the overall
similar behavior of U-p53 AZ . Subsequent ANOVA
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Table 1. Baseline demographics and neuropsychological classification of the included subjects
Total number of subjects, N
Classification at baseline, N (%)
NMC
SMC
MCI
OD
AD
Classification at last follow-up, (N %)
NMC
SMC
MCI
OD
AD
Follow-up, median (months)***
Age, median (IQR)**
Female, N (%)
APOE4, N (%)a***
Positive (%)
Negative (%)
[Not available]
Amyloid categories - baseline, N (%)a***
Negative
Uncertain
Moderate
High
Very high
[Not available]

All subjects
479

Non-AD subjects
270

AD subjects
209

74 (15%)
163 (34%)
98 (21%)
3 (1%)
141 (29%)

72 (27%)
157 (58%)
38 (14%)
3 (1%)
0 (0%)

2 (1%)
6 (3%)
60 (29%)
0 (0%)
141 (68%)

65 (14%)
142 (30%)
48 (10%)
15 (3%)
209 (44%)
22 (0-67)
72 (67-78)
239 (50%)

65 (24%)
142 (53%)
48 (18%)
15 (6%)
0 (0%)
55 (34-91)
71 (66-76)
136 (50%)

0 (0%)
0 (0%)
0 (0%)
0 (0%)
209 (100%)
0 (0-18)
74 (69-79)
103 (49%)

217 (46%)
255 (54%)
7

88 (33%)
182 (67%)
0

129 (64%)
73 (36%)
7

177 (42%)
19 (5%)
35 (8%)
97 (23%)
94 (22%)
57

156 (61%)
14 (5%)
26 (10%)
46 (18%)
16 (6%)
12

21 (13%)
5 (3%)
9 (6%)
51 (31%)
78 (48%)
45

AD: Alzheimer’s disease; CN: cognitively normal; IQR: interquartile; MCI: mild cognitive impairment; NMC: no memory complaints; non-AD: individuals classified
other than AD (as CN, MCI, or OD); OD: other dementia; SMC: subjective memory complaints; The total number of subjects involved, regardless of the groups or
subgroup, refers to the neuropsychological classification at the last follow-up. The distribution in subgroups (non-AD or AD) at baseline is organized according to the
final classification; a Percentages were calculated on the individuals included in the analyses (i.e., missing subjects [Not available] were not considered in this analysis);
P-values in the parameters column resulted from the comparison of non-AD and AD subjects for the specific entry. Numerical values were compared using a standard
T-test, categorical values by Fisher’s Exact test; ** P≤0.01; *** P≤0.001.

testing was performed to compare mean levels of
U-p53 AZ, underscoring a significant difference across
neuropsychological groups (P<0.001) (Figure 1A), which
was further substantiated by Tukey test for difference
across different groups (P<0.001). Accordingly, plasma
U-p53 AZ could accurately and reliably discriminate
subjects at the asymptomatic stage (NMC and SMC)
from those with AD (AUC=99.8%; 95% CI: 99.6-100.0%)
with a sensitivity of 95.0% and specificity of 99.6%.
Similarly, the sensitivity and specificity of U-p53 AZ to
differentiate subjects at the early symptomatic stage
(MCI) from those with neuropsychological AD status
(AUC=95.7%; 95% CI: 92.8-98.5%) were 95.0% and
91.8%, respectively. This was confirmed categorizing
individuals at final neuropsychological diagnosis (i.e., last
visit) according to their baseline U-p53AZ levels, which
were significantly different across groups (ANOVA;
P<0.001) and even among individuals with MCI and
AD (Tukey test; P<0.001) (Figure 1B). Interestingly,
baseline levels of U-p53 AZ in individuals with stable

neuropsychological MCI through the study (i.e. baseline
and final diagnosis; N=38) were significantly lower
(Tukey test; P<0.001) compared to those MCI patients
that developed AD (N=60), suggesting that individuals
with MCI who had high U-p53 AZ levels at baseline
are more likely to convert to neuropsychological AD
status over time. Similarly, individuals who changed
their neuropsychological classification from CN to AD
(N=8) presented significantly higher baseline levels of
U-p53AZ compared with those (N=207) who had a stable
CN profile (Tukey Test; P=0.003). A similar trend of higher
U-p53 AZ was noted for CN individuals (N=17) whose
neuropsychological classification changed to MCI over
the course of the study (Tukey Test; P<0.001).
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the neuropsychological classification (Figure 2,
Supplementary Material Table 2).
Given the promising trend observed for U-p53 AZ,
with the available dataset its association to the AD
neuropsychological status was further investigated
in subsets comparing CN with AD and MCI with AD
(Supplementary Material Table 3). In both subgroups,
U-p53 AZ consistently scored a high performance
(AUC>95%) in differentiating respectively CN and MCI
individuals from AD ones, indicating its association
with AD defined on the basis of neuropsychological
assessment.

Figure 1. Boxplots showing the average levels of U-p53AZ
in different neuropsychological classifications. A) U-p53AZ
levels across diagnostic groups as defined at baseline. B)
U-p53AZ levels across diagnostic groups as defined at the
final follow-up (i.e., the last visit) used in this study

The potential of U-p53AZ to identify individuals
at risk of AD neuropsychological diagnosis

AD: Alzheimer’s disease; MCI: mild cognitive impairment; NMC: no memory
complaints; SMC: subjective memory complaints. Color-coding in Figure 1A: blue
background: low U-p53AZ; green background: intermediate background U-p53AZ;
red: high U-p53AZ; grey dots: individuals whose status was non-AD at the final
diagnosis; yellow dots: individuals whose status was AD at the final diagnosis.
The Y axis reports AZ 284® concentration (fmol/10 μL) and is used as a readout of
U-p53AZ, after which is labelled. *** P<0.001

Diagnostic performance of U-p53AZ and Aβ-PET
to detect AD neuropsychological status

Both U-p53 AZ levels and amyloid categories (as
determined by Aβ-PET) were evaluated, based
on availability, in a subset of respectively 476
and 419 subjects to detect individuals at high risk
of AD progression based on assessment of the
n e u ro p s y c h o l o g i c a l c l a s s i f i c a t i o n . I n d i v i d u a l s
were classified in five diagnostic groups: 1) “CN”, 2)
“MCI”, 3) “CN individuals whose neuropsychological
classification changed to MCI by the end of the followup” (cognitive decline [CD] progressors), 4) “CN or MCI
individuals neuropsychological classification changed
to AD by the end of the follow-up” (AD progressors),
and 5) “individuals with neuropsychological AD”
(AD). Classification of the different diagnostic groups
by U-p53 AZ categories (“low U-p53 AZ ”, “intermediate
U-p53 AZ ” and “high U-p53 AZ ”) indicated that the
majority of subjects belonging to the AD progressors
and AD groups were classified to have intermediate
to high U-p53AZ measurements (respectively, 96% and
99%) (Supplementary Material, Figure 2A and Table
4). The same dataset, classified by amyloid categories
as estimated within each neuropsychological group,
was in line with the U-p53 AZ classification, as most
individuals who were CN presented low amyloid
burden (Supplementary Material, Figure 2B and Table
4). However, individuals with AD and those whose
neuropsychological classification changed to AD were
less clearly assigned to risk amyloid categories, as high
and very high amyloid (namely, 79% for AD subjects and
78% for AD progressors). MCI subjects were similarly
identified between risk amyloid categories and U-p53AZ
status (47% and 39%). For further clarification over the
detection potential of U-p53 AZ for at-risk groups, the
subsequent analyses focused on assessing its prognostic
performance.

T h e p e r f o r m a n c e o f U - p 5 3 AZ a n d A β - P E T
for AD diagnosis was evaluated based only on
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the same diagnostic group). By time-dependent ROC
curves, the prognostic performance of U-p53AZ to predict
neuropsychological AD was superior to amyloid brain
imaging by Aβ-PET 36 and 72 months after baseline
assessment (Figure 3). The corresponding AUC values of
both markers are displayed in Supplementary Material
(Table 6), confirming that the prognostic performance of
U-p53AZ was significantly better than that of Aβ-PET for
identification of individuals whose neuropsychological
status would change in time to AD (P<0.001).

Figure 2. ROC curves comparing the performance
of U-p53AZ and Aβ-PET (CL numerical values) to
differentiate AD from non-AD individuals at baseline
neuropsychological diagnosis

Figure 3. Prognostic performance of U-p53AZ and AβPET (CL-based Aβ categories) in predicting the change of
neuropsychological classification to AD

AUC: area under the curve; CI: confidence interval.

Prognostic performance of U-p53AZ to predict
the onset of AD as assessed through the
neuropsychological status
Due to the promising performance of U-p53 AZ
in identifying individuals at risk of changing
neuropsychological classification to AD, a timeindependent evaluation of prognostic performance to
differentiate AD from non-AD was performed on the
dataset as classified at final neuropsychological
diagnosis (Supplementary Material, Table 5). The
baseline quantification of U-p53AZ and of Aβ-PET were
included and compared in the analysis. Based on subject
classification at final neuropsychological diagnosis,
U-p53AZ presented a significantly greater performance
compared to Aβ-PET, underscoring the potential
of U-p53AZ in prognostic settings (U-p53 AZ AUC [95%
CI]=99.0% [98.2-99.8%], Aβ-PET AUC [95% CI]=83.5%
[79.5-87.5%], P<0.0001).
Baseline levels of U-p53 AZ were also considered to
predict neuropsychologically diagnosed AD at different
timepoints following plasma collection, independently of
the initial classification. Time-dependent ROC analyses
were thus performed to gain insight into the prognostic
performance at specific timepoints. Samples from nonAD individuals who changed neuropsychological
group to AD were compared with samples from nonAD individuals whose status remained non-AD (either
changing to another non-AD group, or remaining in

ROC curves show the performance of U-p53AZ and Aβ-PET in predicting the onset
of neuropsychological AD in non-AD individuals at 36 and 72 months following
baseline assessment compared to individuals whose neuropsychological remained
stable or progressed to another non-AD group (values in Supplementary Material,
Table 5). AUC: area under the curve; CI: confidence interval.

The probability of progression due to U-p53AZ or
due to other risk factors
To assess the relevance of U-p53AZ as prognostic AD
biomarker throughout time, Cox proportional hazards
models were created based on either a single risk factor
(U-p53 AZ) or different combinations of multiple risk
factors (including U-p53 AZ and traditionally accepted
factors as Aβ-PET, APOE ε4 and age) (Supplementary
Material, Table 7). Kaplan-Meier curves were then
plotted for U-p53AZ alone (Figure 4A, dividing the subject
population among “low” and “intermediate-high” in
reference to the preliminary U-p53AZ threshold adopted
in the present study) and for a multifactorial model based
on U-p53AZ, Aβ-PET, APOE ε4 and age (Figure 4B).
Both models precisely divided the population in high
and low risk of neuropsychological AD onset based on
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the selected thresholds and strata (P<0.001). Hazards
ratios (HRs) were estimated for risk factors included
in adjusted and non-adjusted models (Supplementary
Material, Table 8). Evaluation of an adjusted model
normalized for all the factors further enabled the direct
comparison of HRs across risk factors, indicating that
U-p53 AZ is the major contributor and an independent
predictor for cognitive decline to neuropsychological AD
(HR=2.92, P<0.0001).
Figure 4. Kaplan-Meier survival curve for dementia-free
survival

Plots for A) U-p53AZ positivity and B) all the risk factors.

Discussion
In the last years, there has been a growing interest in
blood-based biomarkers allowing early identification
of individuals at risk for developing AD (10). Despite
these efforts, none of the studied blood-based biomarkers
have yet been included in the screening protocols for
the assessment of AD risk (3), leaving more than half of
individuals with AD dementia without a formal diagnosis
(10). Additionally, clinical intervention trials suffer from
the lack of accessible prognostic biomarkers, leading
to inadequate enrolment of individuals at risk of AD.
Implementation of minimally-invasive and reliable bloodbased biomarkers could respond to these unmet needs
increasing the accuracy of AD diagnosis while improving

clinical trial enrolment (9, 10). This is particularly relevant
in the coming years due to aging of the population
and the subsequent increase in the numbers of patients
receiving the clinical diagnosis of AD (37).
One of the recently discovered blood-based biomarker
candidates is a conformational variant of p53. Although
p53 is mostly known for its role as tumor suppressor,
it is now clear that p53 is regulating cell fate decisions
and preventing neurodegeneration through multiple
mechanisms, including DNA damage repair, protection
from oxidative stress, support of axonal regeneration,
neuronal outgrowth and synaptic function as well as
repression of β-site amyloid precursor protein-cleaving
enzyme 1 (BACE1) expression (38-43). Nevertheless,
its neuroprotective function becomes gradually lost
throughout the AD continuum, as exposure to increasing
amounts of Aβ and ROS/RNS leads to unfolding of
the p53 protein resulting in elevated levels of the p53
conformational variant, identified as U-p53 (17-19, 44).
U-p53 has previously been detected in peripheral cells
derived from MCI and AD individuals and was shown
to be predictive of the onset of AD (21-23). Although
promising, these preliminary studies were based on
limited patient numbers and conventional techniques,
such as flow cytometry and ELISA, using commercially
available antibodies (21, 22). Assessment of U-p53 has
now been improved by the development of a novel
antibody (2D3A8) specifically targeting the AD clinically
relevant U-p53 conformational variant (U-p53 AZ) (24,
25). To further improve its analytical performance,
U-p53AZ was quantified by the AlzoSure® Predict method,
a LC-ESI/MS/MS sequential technique using plasma
samples from individuals at different stages of the AD
continuum, available through the longitudinal AIBL
cohort. Due to its high specificity in comparison with
conventional techniques and its increasing accessibility
at lower costs, MS has been widely used in several bloodbased biomarker studies (45-47). By using this technique,
the present study aimed to assess whether quantification
of U-p53AZ was able to assign individuals to the correct
diagnostic group and determine its performance for
predicting the onset of AD at the asymptomatic and
symptomatic stages.
The present study confirms and further expands
former findings over the potential of U-p53 AZ
implementation in prognostic tests for AD (25). First,
analysis of U-p53 AZ distribution (through LC-MS/
MS AZ 284 ® detection) across diagnostic groups both
at baseline and last available assessment markedly
revealed higher levels of the misfolded conformation in
plasma samples of MCI and AD individuals, as well as
of those whose classification changed (i.e., worsening of
neuropsychological status to MCI or AD) over the time
of the study. The higher U-p53AZ levels in individuals at
risk of progression were also suggestive of a possible role
of U-p53AZ as predictor of future AD. Secondly, the levels
of U-p53AZ associated with baseline neuropsychological
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diagnoses of AD, in line with the diagnostic performance
of Aβ-PET in discriminating AD from non-AD subjects.
Such observation lead also to consistent results in selected
subgroups, in which U-p53AZ reliably differentiated both
CN and MCI individuals from AD ones (respectively,
AUC CN vs AD[95% CI]=99.8% [99.6-100.0%] and AUCMCI
[95% CI]=95.7% [92.8-98.5%]). Third, we noted that
vs AD
the promising association of increased U-p53 AZ levels
with individuals already AD or at risk of deterioration
was further confirmed through U-p53 AZ categories
(subdivided in “low U-p53 AZ”, “intermediate U-p53 AZ”
and “high U-p53 AZ”): individuals progressing towards
AD or already diagnosed as AD majorly presented
intermediate to high levels of U-p53AZ. Interestingly, the
same analysis revealed that progressors to CD (as CN
individuals reclassified as MCI by the end of followup) were mostly characterized by low U-p53AZ levels,
suggesting the prognostic specificity of U-p53AZ categories
for AD detection rather than for the onset of cognitive
impairment. The prognostic potential was further
confirmed by time-independent and -dependent analyses
of performance for both U-p53AZ and Aβ-PET, in which
the former proved to be a powerful and precise predictor
of AD onset, even long time before the formal diagnosis.
Notably, while AUC values for Aβ-PET ranged between
87% and 92%, in the same subset of samples and time
period (36-90 months) U-p53AZ presented a consistently
and significantly higher performance (≥98%, P<0.001).
Finally, Cox proportional hazard models weighting the
contribution of different factors (dichotomous APOE ε4
allele status, Aβ-PET, age, gender, as well as U-p53AZ)
confirmed the important role of U-p53AZ in predicting AD
onset for detection in the intermediate to high threshold,
as defined here in an arbitrarily assigned threshold.
Inclusion of a single factor, as U-p53AZ, was sufficient to
correctly predict present or future AD classification.
Generally, the herein presented results confirm and
expand the ones from a previously published study using
a similar technique. However, by including a larger study
cohort, the predictive performance of U-p53AZ was found
to be further improved (25). When comparing to a model
based on magnetic resonance imaging (MRI), PET, CSF
and covariates (48), the predictive potential of U-p53AZ
was higher and without the limitations associated with
costs and invasiveness.
While the development of blood-based biomarkers
was initially intended for diagnostic purposes, their
potential in accurate prediction of the onset of AD in nondemented CN adults and MCI patients is gaining more
interest (49). As an example, plasma phospho-tau181
levels were recently shown (50) to predict the change of
neuropsychological classification of individuals from
SMC to AD with AUC values comparable to U-p53AZ (51).
This poses the question whether screening based on an
unique biomarker instead of a panel could be used for
the precise identification of individuals who are prone to
develop AD dementia. The data retrieved and used in the
present study was largely based on imaging techniques,

and the results herein reported majorly addressed
the U-p53 AZ performance within this framework. The
achieved results indicate a promising trend on future
applications of U-p53AZ as unique prognostic blood-based
biomarker readily available for population screening,
although by design this study was not developed to draw
a final conclusion regarding the positioning of U-p53AZ
in comparison with that of traditionally accepted CSF
biomarkers. The ongoing follow-up study, as detailed
in a subsequent passage of the discussion, could further
confirm the observed trend.
Although our findings are suggestive of the predictive
potential of U-p53AZ, the results herein described are
based on a single longitudinal study, largely lacking
follow-up data on amyloid burden. Hence, certain
subjects were assigned to AD without knowing the
amyloid status. Moreover, for some individuals the
available Aβ status was initially present but negative on
PET imaging, technically not classifying as AD dementia,
while lacking sufficient follow-up data. Insufficient
follow-up can give the false diagnosis of non-AD, while
the marker is known for its diagnostic power since
presents a later onset through PET (52). This lead to a
discrepancy between the assigned AD classification and
the performance of amyloid, despite the body of literature
supporting amyloid positivity as the gold standard for
AD dementia diagnosis.
Further studies will ensure a more complete
follow-up, including different biomarkers for clinical
AD confirmation as Aβ biomarkers (Aβ42), pathologic
Tau biomarkers (total and phopsho-181) and severity
staging through neurodegenerative biomarkers (NFL)
(3), enabling a more rigorous adherence to the clinical
classification. These studies will also include larger
sample numbers provided by different centers to validate
the performance of U-p53AZ in predicting onset of AD
dementia and to determine a final cut-off that can be
integrated in clinical practice for stratification of CN
individuals who are at high risk to develop AD dementia.
The ongoing follow-up study uses additional longitudinal
data from different cohorts and centers, including
individuals from Europe and USA, to validate the herein
presented findings and to compare and correlate the
potential of U-p53 AZ as blood-based biomarker with
traditionally studied markers of AD pathology.
A d d i t i o n a l l y, a s s u m i n g t h a t p re v e n t i n g t h e
development of AD dementia could result in the reduced
increase of U-p53AZ levels, the use of U-p53AZ could be
evaluated to support patient stratification in clinical trials
and assessment of DMTs effectiveness.
In conclusion, the present study demonstrated the
high performance of U-p53 AZ to predict the onset of
AD in asymptomatic individuals or individuals early
symptomatic stage, as early as six years prior to a
neuropsychological AD diagnosis. We believe that
quantification of U-p53AZ through AlzoSure® Predict has
the potential to be implemented in screening strategies,
allowing improved stratification of individuals at high
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risk to develop AD dementia in clinical intervention trials
to subsequently support the development of effective
DMTs. Ultimately, early detection of AD could ensure
timely prescription of DMTs to maximize their efficacy.
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